Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have received a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $619.4091.

A number of equities research analysts have issued reports on the company. Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a research note on Wednesday, August 5th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Piper Sandler boosted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th.

Thermo Fisher Scientific Stock Down 1.4%

TMO stock opened at $621.87 on Tuesday. The business’s 50-day moving average price is $558.64 and its 200-day moving average price is $512.08. The stock has a market cap of $229.94 billion, a P/E ratio of 33.45, a PEG ratio of 2.53 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently made changes to their positions in TMO. VELA Investment Management LLC grew its stake in shares of Thermo Fisher Scientific by 15.7% in the 2nd quarter. VELA Investment Management LLC now owns 11,167 shares of the medical research company’s stock worth $5,599,000 after buying an additional 1,513 shares in the last quarter. HighTower Advisors LLC raised its position in shares of Thermo Fisher Scientific by 9.8% during the 2nd quarter. HighTower Advisors LLC now owns 159,181 shares of the medical research company’s stock valued at $79,807,000 after buying an additional 14,180 shares in the last quarter. Advus Financial Partners LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $250,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Thermo Fisher Scientific in the second quarter worth about $6,969,000. Finally, California State Teachers Retirement System increased its stake in Thermo Fisher Scientific by 49,331.5% during the second quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company’s stock worth $141,711,778,000 after acquiring an additional 282,082,924 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.